2026 ACR JIA Guidelines: Early Biologics, Reversal on Methotrexate

The American College of Rheumatology (ACR) released updated guidelines for the treatment and management of juvenile idiopathic arthritis (JIA) today, May 13, issuing its most comprehensive JIA guidance to date. Spanning 4 manuscripts covering systemic JIA, non-systemic JIA, nonpharmacologic management and monitoring, and JIA-associated chronic anterior uveitis, the 2026 guidelines represent a significant revision — and in some cases a direct reversal — of positions established in the prior 2019 and 2022 updates.¹

The overarching philosophy is unmistakable: treat early, treat aggressively, and remove the procedural barriers that have historically delayed access to effective therapy.

"The guidelines encourage early use of DMARDs with attention paid to risk factors that would suggest the need for early escalation of treatment," said lead investigator Karen Onel, MD, Chief of the Pediatric Rheumatology Division at the Hospital for Special Surgery. "To that end, use of biologic DMARDs without the requirement of 'failure' of conventional synthetic disease-modifying antirheumatic drugs was supported. Any required waiting period is too long if a child is not doing well."²

Oral Methotrexate Over Subcutaneous

Perhaps the most immediately practice-changing recommendation is a reversal on methotrexate route of administration. The 2019 ACR JIA guidelines conditionally recommended subcutaneous over oral methotrexate for polyarthritis — a position based on low-quality evidence and largely driven by assumptions about bioavailability at higher doses.³ The 2026 guidelines now conditionally recommend oral methotrexate over subcutaneous administration across all relevant non-systemic JIA phenotypes, including polyarthritis, oligoarthritis, enthesitis, dactylitis, TMJ arthritis, and — notably — JIA-associated chronic anterior uveitis (CAU). The shift reflects evolving evidence on comparable efficacy alongside the practical burden that subcutaneous injections impose on pediatric patients and families.¹,² "Recommendations supporting the use of oral over subcutaneous methotrexate is a change from previous standard of care," Onel stated.²

Early bDMARD Access Without Mandatory csDMARD Failure

Across non-systemic JIA phenotypes, the 2026 guidelines support movement toward biologics without requiring documented failure of a csDMARD first in all cases. For polyarthritis, DMARDs — including bDMARDs — are strongly recommended as first-line therapy, and TNF inhibitors are conditionally recommended as the first biologic. For oligoarthritis, bDMARDs are strongly recommended upon inadequate response to NSAIDs, intraarticular glucocorticoids (IAGCs), and a first-line csDMARD — though with the prior requirement for csDMARD failure removed as an absolute gate in appropriate clinical contexts. The guidelines identify specific risk factors for poor outcomes that should prompt earlier escalation, including ankle, wrist, sacroiliac joint, hip, or TMJ involvement; erosive disease; enthesitis; delayed diagnosis; elevated inflammatory markers; RF or CCP positivity; and symmetric disease.¹

Onel noted the guideline's utility beyond subspecialty practice: "Many children in the US and around the world do not have access to expert pediatric rheumatology care. These guidelines should assist not only pediatric rheumatologists but adult rheumatologists and pediatricians in choosing best treatment for children with JIA."²

Systemic JIA: Biologics First, NSAIDs and Glucocorticoids Out

For systemic JIA (sJIA) without macrophage activation syndrome (MAS), the 2026 guidelines issue a strong recommendation for bDMARD therapy — specifically an IL-1 inhibitor or IL-6 inhibitor — as first-line treatment, with no preferred agent between the two classes. Simultaneously, the guidelines issue strong recommendations against NSAIDs as initial monotherapy and against csDMARDs as initial monotherapy, and a conditional recommendation against oral glucocorticoids as initial monotherapy. This consolidates the direction first articulated in the 2022 sJIA update and extends it with additional nuance for residual arthritis scenarios. For sJIA with MAS, systemic glucocorticoids remain strongly recommended as part of initial therapy alongside bDMARD therapy.¹

The 2026 update also introduces a conditional recommendation for routine screening for sJIA-associated lung disease (sJIA-LD) — a complication that has received growing attention in the literature over the past several years. Critically, the guidelines include a strong recommendation that the presence or development of lung disease should not be considered an absolute contraindication to the use of IL-1 or IL-6 inhibitors, a point of contention in clinical practice following reports associating these agents with sJIA-LD.¹

Anti-Drug Antibody Monitoring Discouraged

Across polyarthritis, oligoarthritis, enthesitis, dactylitis, and TMJ arthritis phenotypes, the 2026 guidelines include a new conditional recommendation against routinely monitoring anti-drug antibodies in patients on bDMARDs — a pragmatic update that reflects the limited clinical utility of routine ADA monitoring outside of specific clinical scenarios.¹

Mental Health Screening Now Explicitly Recommended

The nonpharmacologic management section formally incorporates a conditional recommendation for screening for mental health concerns in all patients with JIA whenever possible, with referral for appropriate treatment. The inclusion formalizes an area of care that has historically been inconsistently addressed in rheumatology practice. Physical therapy, occupational therapy, and physical activity are conditionally recommended regardless of concurrent pharmacologic therapy. A strong recommendation against use of specific diets alone to treat JIA is included, though discussion of a healthy, age-appropriate diet is encouraged.¹

Deprescribing and Tapering Guidance Formalized

The guidelines provide new structured guidance on DMARD deprescribing. For non-systemic JIA in clinical remission on combination DMARDs, tapering or stopping csDMARDs first before bDMARDs or tsDMARDs is conditionally recommended. Imaging of joints difficult to assess is conditionally recommended before tapering. In both systemic and non-systemic JIA, restarting the most recently effective regimen — rather than initiating a new regimen — is conditionally recommended for patients who flare after tapering.¹

The full recommendation sets are published across companion manuscripts in Arthritis & Rheumatology and Arthritis Care & Research. As with prior iterations, nearly all recommendations carry low or very low quality of evidence ratings, and the majority are conditional — a persistent limitation of the JIA evidence base that the guidelines acknowledge.¹

References

1. American College of Rheumatology. 2026 ACR Juvenile Idiopathic Arthritis (JIA) Guidelines Summary. May 13, 2026. https://rheumatology.org/juvenile-idiopathic-arthritis-guideline

2. American College of Rheumatology. The American College of Rheumatology releases updated guidelines for treatment of juvenile idiopathic arthritis. Press release. May 13, 2026. https://rheumatology.org/press-releases/the-american-college-of-rheumatology-releases-updated-guidelines-for-treatment-of-juvenile-idiopathic-arthritis

3. Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. Arthritis Care Res. 2022;74(4):521–537. doi:10.1002/acr.24853